Senzime launches OnZurf Probe for preclinical use

Uppsala, December 19, 2016. Senzime launches OnZurf Probe for use in preclinical research. Onzurf Probe is a new generation of microdialysis probe (catheter) that allows organ-specific monitoring after surgery on organs such as the esophagus, bowel and liver. Onzurf Probe has a unique mode of attachment to the target organ, allowing easy placement of the microdialysis catheter on the surface of the organ. This non-invasive technique obviates the need for penetrating surgical instruments that can cause tissue trauma and stress during placement of the probe.

OnZurf Probe is proven in preclinical research. Earlier preclinical study results have shown that the samples taken by OnZurf Probe were consistent with histo-pathological findings of lack of oxygen (hypoxemia) in the intestinal wall. The study also showed that measurements with OnZurf Probe from the intestinal wall can be a useful tool for early detection of complications in the small intestine after surgery. More information about the study is available online via this link.

"The preclinical research is the basis for the clinical research and therefore it is important that these studies are conducted appropriately, both from an animal protection ethical point of view and a future clinical perspective. OnZurf Probe makes preclinical sampling easy and safe," said Lena Söderström, CEO Senzime AB.

OnZurf Probe for preclinical use is now available to order; delivery is anticipated in mid-January 2017. CE marking process for OnZurf Probe for patient use is ongoing, and the system is expected to be launched during the first part of 2017.

For further information, please contact:
Lena Söderström, CEO of Senzime AB
Tel: +46-708-16 39 12, email: lena.soderstrom@senzime.com

TO THE EDITORS

About Senzime

Senzime develops unique patient-oriented monitoring systems that make it possible to assess patients' biochemical and physiological processes before, during and after surgery. The portfolio of technologies includes bedside systems that enable automated and continuous monitoring of life-critical substances such as glucose and lactate in both blood and tissues, as well as systems to monitor patients' neuromuscular function perioperatively and in the intensive care medicine setting. The solutions are designed to ensure maximum patient benefit, reduce complications associated with surgery and anesthesia, and decrease health care costs. Senzime operates in growing markets that in Europe and the United States are valued in excess of $10 billion. The company's shares are listed on AktieTorget (ATORG: SEZI) www.senzime.com